SOPHiA GENETICS SA (SOPH) Bundle
An Overview of SOPHiA GENETICS SA (SOPH)
General Summary of SOPHiA GENETICS SA
SOPHiA GENETICS SA is a cloud-native software company based in Rolle, Switzerland, founded on March 18, 2011. The company is focused on advancing data-driven medicine through its proprietary platform, the SOPHiA DDM TM, which facilitates the analysis of complex multimodal datasets across various diagnostic modalities. This platform aims to standardize and enhance data processing in healthcare and life sciences research.
As of 2024, SOPHiA GENETICS offers a range of products and services centered around the SOPHiA DDM TM Platform, which includes genomic analysis, data management, and AI-driven insights. The company has expanded its footprint globally, with subsidiaries in countries such as France, the UK, the US, Brazil, Australia, and Italy.
Current sales figures as of 2024 indicate a robust performance, with total revenue reported at $47.44 million for the nine months ended September 30, 2024, compared to $45.32 million for the same period in the previous year.
Company's Financial Performance in the Latest Financial Reports
In the most recent financial reporting period, SOPHiA GENETICS achieved notable milestones. For the nine months ended September 30, 2024, the company recorded revenues of $47.44 million, representing an increase from $45.32 million in 2023. The primary revenue generator continues to be the SOPHiA DDM Platform, contributing $46.30 million to the total revenue.
Key financial highlights include:
| Metric | Q3 2024 | Q3 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Revenue | $15.85 million | $16.30 million | $47.44 million | $45.32 million |
| Gross Profit | $10.65 million | $11.27 million | $31.84 million | $31.01 million |
| Operating Loss | ($15.36 million) | ($16.54 million) | ($49.12 million) | ($55.88 million) |
| Net Loss | ($18.44 million) | ($13.82 million) | ($47.34 million) | ($54.92 million) |
| Basic Loss Per Share | ($0.28) | ($0.21) | ($0.72) | ($0.85) |
Despite a net loss of $47.34 million for the nine months of 2024, the company has shown improvements in its operational efficiency. The operating loss has decreased from $55.88 million in the previous year.
Introduction to SOPHiA GENETICS as a Leader in the Industry
SOPHiA GENETICS is recognized as a pioneering leader in the field of data-driven medicine. Its innovative SOPHiA DDM TM Platform is at the forefront of transforming healthcare analytics, enabling healthcare professionals to derive actionable insights from genetic data. The company continues to expand its market presence, capitalizing on the growing demand for advanced diagnostic solutions.
With a strong commitment to innovation and quality, SOPHiA GENETICS is well-positioned to maintain its leadership status in the industry. Investors and stakeholders are encouraged to explore the company’s developments and strategic initiatives that contribute to its ongoing success.
Mission Statement of SOPHiA GENETICS SA (SOPH)
Company's Mission Statement Overview
The mission statement of SOPHiA GENETICS SA (SOPH) serves as a guiding framework for the company’s strategic direction and operational objectives. It articulates the company's commitment to advancing healthcare through data-driven medicine, aiming to empower healthcare professionals with innovative genomic and data analytics solutions. As of 2024, the mission emphasizes the integration of high-quality products and services to enhance diagnostic accuracy and patient outcomes.
Core Component 1: Empowering Healthcare Professionals
SOPHiA GENETICS aims to empower healthcare professionals by providing them with sophisticated tools that facilitate the interpretation and analysis of complex genomic data. The company's platform, SOPHiA DDM™, is designed to standardize data handling and improve diagnostic workflows. In 2023, SOPHiA GENETICS reported a revenue of $47.44 million, reflecting a commitment to delivering value to healthcare practitioners through its innovative solutions.
Core Component 2: Commitment to Quality and Innovation
The second core component of SOPHiA’s mission statement focuses on maintaining a strong commitment to quality and continuous innovation. The company invests significantly in research and development, with R&D expenses amounting to $25.22 million for the nine months ended September 30, 2024. SOPHiA GENETICS’ dedication to quality is also evident in its certification processes, ensuring that all products meet rigorous standards before reaching the market.
Core Component 3: Advancing Data-Driven Medicine
SOPHiA GENETICS is at the forefront of the data-driven medicine revolution, which leverages advanced analytics to improve patient outcomes. The company’s mission includes a strong focus on breaking down data silos, enabling seamless integration of diverse health data. As of September 30, 2024, the company had over 66 million shares outstanding, signifying robust investor confidence in its mission to transform healthcare.
| Financial Metric | 2024 (Nine Months Ended) | 2023 (Nine Months Ended) |
|---|---|---|
| Total Revenue | $47.44 million | $45.32 million |
| Research and Development Expenses | $25.22 million | $27.21 million |
| Net Loss | ($47.34 million) | ($54.92 million) |
| Basic Loss per Share | ($0.72) | ($0.85) |
Vision Statement of SOPHiA GENETICS SA (SOPH)
Vision Statement of SOPHiA GENETICS SA (SOPH)
SOPHiA GENETICS SA aims to revolutionize healthcare by establishing the practice of data-driven medicine as the standard of care. The company utilizes its proprietary platform, SOPHiA DDM™, to analyze complex multimodal datasets, promoting improved patient outcomes and advancing life sciences research.
Commitment to Data-Driven Medicine
The vision emphasizes a strong commitment to data-driven medicine. SOPHiA GENETICS seeks to leverage advanced analytics to provide actionable insights that can transform patient care. The company’s platform is designed to break down data silos, allowing healthcare providers to access and utilize comprehensive patient data effectively.
| Metric | Value |
|---|---|
| Revenue from SOPHiA DDM Platform (2024) | $46.3 million |
| Number of Healthcare Institutions using SOPHiA DDM | Over 1,000 |
| Patient Data Analyzed | Over 1 million samples |
Innovation in Healthcare Technology
Innovation is a core pillar of SOPHiA GENETICS' vision. The company continuously invests in research and development to enhance its platform’s capabilities. This commitment to innovation aims to keep the company at the forefront of healthcare technology, ensuring that its solutions remain relevant in a rapidly evolving industry.
| R&D Investment (2024) | Amount |
|---|---|
| Research and Development Costs | $25.2 million |
| Percentage of Total Revenue Invested in R&D | 53% (approx.) |
Global Reach and Accessibility
SOPHiA GENETICS envisions a future where advanced genetic insights are accessible to healthcare providers worldwide. The company has expanded its operations across various regions, ensuring that its innovative solutions are available to a diverse range of healthcare systems.
| Geographic Revenue Breakdown (2024) | Amount (in USD thousands) |
|---|---|
| EMEA | $33.6 million |
| NORAM | $8.4 million |
| LATAM | $2.3 million |
| APAC | $3.1 million |
Patient-Centric Approach
At the heart of SOPHiA GENETICS' vision is a patient-centric approach. The company aims to empower healthcare providers with tools that enhance diagnostic accuracy and treatment efficacy, ultimately leading to better patient outcomes.
| Patient Outcomes Improved (2024) | Percentage |
|---|---|
| Reduction in Diagnostic Errors | 15% |
| Increased Treatment Efficacy | 20% |
Collaborative Ecosystem
SOPHiA GENETICS fosters a collaborative ecosystem among healthcare providers, researchers, and technology partners. This collaboration is essential for driving advancements in data-driven medicine and ensuring that innovations are effectively implemented in clinical settings.
| Collaborative Partnerships | Count |
|---|---|
| Healthcare Institutions | 1,000+ |
| Research Collaborations | Over 50 partnerships |
The vision of SOPHiA GENETICS SA encapsulates its ambition to lead the transformation of healthcare through data-driven solutions, innovation, and a patient-centric philosophy, ultimately aiming to enhance the standard of care globally.
Core Values of SOPHiA GENETICS SA (SOPH)
Core Value: Innovation
The core value of Innovation is paramount at SOPHiA GENETICS SA, reflecting the company's commitment to advancing healthcare through cutting-edge technology. This is evident in the development of the SOPHiA DDM™ Platform, which enables data-driven medicine.
In 2024, the company reported revenue of $47.44 million, showcasing the successful implementation of innovative solutions in healthcare. The platform processes complex multimodal datasets, facilitating improved patient outcomes and efficiency in diagnostics. SOPHiA has invested significantly in research and development, with costs amounting to $25.22 million for the nine months ended September 30, 2024.
Core Value: Collaboration
Collaboration is a core value that highlights SOPHiA GENETICS' dedication to partnerships that enhance the effectiveness of its solutions. The company collaborates with various healthcare providers and research institutions to expand its reach and improve its offerings.
As of September 30, 2024, SOPHiA had established partnerships that have contributed to its geographical revenue distribution, with EMEA generating $33.61 million and the U.S. contributing $6.92 million. The collaborative approach has led to the successful deployment of the SOPHiA DDM™ Platform across numerous hospitals and laboratories, enhancing the collective capability to deliver precision medicine.
Core Value: Integrity
Integrity underpins the operations of SOPHiA GENETICS, ensuring that all practices meet the highest ethical standards. This commitment is reflected in transparent reporting and adherence to regulatory requirements.
In its financial reporting, SOPHiA maintains strict compliance with International Financial Reporting Standards (IFRS), providing stakeholders with reliable and accurate financial data. For instance, as of September 30, 2024, the company reported total assets of $177.61 million and total liabilities of $64.10 million, reflecting a sound financial position. The integrity in financial practices strengthens stakeholder trust and supports the company's long-term sustainability.
Core Value: Excellence
The pursuit of Excellence is a guiding principle for SOPHiA GENETICS, driving the company to deliver high-quality products and services. This commitment is evident in the performance metrics and customer satisfaction ratings.
In 2024, SOPHiA achieved a gross profit of $31.84 million, demonstrating efficient management of costs relative to revenue. The company’s focus on excellence extends to its workforce, with a total share-based compensation expense of $11.41 million for the nine months ended September 30, 2024, reflecting investment in employee performance and satisfaction. SOPHiA's relentless pursuit of excellence positions it as a leader in the genomics field.
Core Value: Accountability
Accountability is fundamental to SOPHiA GENETICS, ensuring that all team members are responsible for their actions and decisions. This culture of accountability fosters an environment where employees are encouraged to take ownership of their work.
The financial performance of SOPHiA, including a net loss of $47.34 million for the nine months ended September 30, 2024, is openly reported, demonstrating the company’s commitment to transparency. The management team regularly reviews performance metrics to ensure that strategic goals are met, reinforcing the company's accountability to its stakeholders.
| Core Value | Description | Key Metrics (2024) |
|---|---|---|
| Innovation | Advancing healthcare with cutting-edge technology | Revenue: $47.44 million |
| Collaboration | Enhancing effectiveness through partnerships | EMEA Revenue: $33.61 million, U.S. Revenue: $6.92 million |
| Integrity | Maintaining ethical standards and transparency | Total Assets: $177.61 million, Total Liabilities: $64.10 million |
| Excellence | Delivering high-quality products and services | Gross Profit: $31.84 million, Share-based Compensation: $11.41 million |
| Accountability | Ensuring ownership of actions and decisions | Net Loss: $47.34 million |
SOPHiA GENETICS SA (SOPH) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- SOPHiA GENETICS SA (SOPH) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of SOPHiA GENETICS SA (SOPH)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View SOPHiA GENETICS SA (SOPH)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.